Your browser doesn't support javascript.
loading
Deubiquitinase JOSD2 stabilizes YAP/TAZ to promote cholangiocarcinoma progression
Acta Pharmaceutica Sinica B ; (6): 4008-4019, 2021.
Artículo en Inglés | WPRIM | ID: wpr-922456
ABSTRACT
Cholangiocarcinoma (CCA) has emerged as an intractable cancer with scanty therapeutic regimens. The aberrant activation of Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are reported to be common in CCA patients. However, the underpinning mechanism remains poorly understood. Deubiquitinase (DUB) is regarded as a main orchestrator in maintaining protein homeostasis. Here, we identified Josephin domain-containing protein 2 (JOSD2) as an essential DUB of YAP/TAZ that sustained the protein level through cleavage of polyubiquitin chains in a deubiquitinase activity-dependent manner. The depletion of JOSD2 promoted YAP/TAZ proteasomal degradation and significantly impeded CCA proliferation

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Tipo de estudio: Estudio pronóstico Idioma: Inglés Revista: Acta Pharmaceutica Sinica B Año: 2021 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Tipo de estudio: Estudio pronóstico Idioma: Inglés Revista: Acta Pharmaceutica Sinica B Año: 2021 Tipo del documento: Artículo